Abbvie (ABBV) EBITDA (2012 - 2026)
Abbvie (ABBV) EBITDA from Mar 31, 2012 to Mar 31, 2026. The TTM Abbvie (ABBV) EBITDA is $16B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Abbvie (ABBV) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +48.62% |
| 3 Years TTM | -1.65% |
| 5 Years TTM | +4.99% |
| 10 Years TTM | +6.52% |
| All Time TTM | +7.08% |
Annual EBITDA change of Abbvie (ABBV)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $4.18B | -73.62% |
| 2025 | $16B | +59.95% |
| 2024 | $9.90B | -26.71% |
| 2023 | $14B | -28.50% |
| 2022 | $19B | +0.90% |
| 2021 | $19B | +55.68% |
| 2020 | $12B | -10.55% |
| 2019 | $13B | +96.19% |
| 2018 | $6.85B | -31.25% |
| 2017 | $9.97B | +2.10% |
| 2016 | $9.77B | +22.77% |
| 2015 | $7.95B | +109.65% |
| 2014 | $3.79B | -37.31% |
| 2013 | $6.05B | -4.57% |
| 2012 | $6.34B | +53.63% |
| 2011 | $4.13B | N/A |
Comparison Abbvie (ABBV) five years EBITDA CAGR with competitors
Abbvie (ABBV) five years EBITDA CAGR is 4.99%.
| Ticker | Name | five years EBITDA CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 30.95% | +519.98% |
| NVO | Novo Nordisk | 25.26% | +405.94% |
| AZN | Astrazeneca plc | 18.02% | +261.03% |
| GILD | Gilead Sciences Inc | 17.19% | +244.38% |
| BMY | Bristol-Myers Squibb Company | 13.61% | +172.56% |
| MRK | Merck & Co Inc | 10.17% | +103.61% |
| JNJ | Johnson & Johnson | 6.13% | +22.87% |
| NVS | Novartis AG | 5.31% | +6.45% |
| AMGN | AMGEN Inc | 4.42% | -11.51% |
| GRFS | Grifols SA | 2.72% | -45.43% |
| GSK | GSK Plc | 1.17% | -76.60% |